Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder

Daniel Umbricht;Markus Niggli;Patricia Sanwald-Ducray;Dennis Deptula;Rema Moore;Waltraud Grünbauer;Lauren Boak;Paulo Fontoura;
the journal of clinical psychiatry 2020 Vol. 81 pp. 0-0
224
umbricht2020therandomized,

Abstract

Growing evidence supports the treatment of MDD through modulation of dysregulated glutamate neurotransmission. This study assessed the putative antidepressant and precognitive effects of decoglurant, a metabotropic glutamate receptor type 2/3 antagonist.

Keywords

keywords:antidepressants; keywords:cognition; keywords:depression; original research; jcp; j clin psychiatry:nlm:journal article; j clin psychiatry:portico:research-article

Access

URL:
http://www.psychiatrist.com/JCP/article/Pages/2020...

Citation

ID: 112180
Ref Key: umbricht2020therandomized,
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
112180
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store